The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MicroRNA oncogenes and tumor suppressors controlling malignant melanoma cell growth, apoptosis, migration, and invasion.
R. W. Georgantas
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
K. Streicher
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
W. Zhu
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
R. Carrasco
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Z. Xiao
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Z. Liu
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
P. Brohawn
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
C. Morehouse
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
D. Tice
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
B. W. Higgs
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
L. Richman
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
P. Kiener
Stock Ownership - AstraZeneca
B. Jallal
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Y. Yao
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca